Skip to main content
. 2021 May 28;39(28):3149–3160. doi: 10.1200/JCO.20.03048

FIG 4.

FIG 4.

Outcome for KMT2A-r acute myeloid leukemia by GO exposure and consolidation approach. (A) DFS by GO exposure for patients treated with GO and HSCT, (B) DFS by GO exposure for patients treated with chemotherapy only, and (C) RR by GO exposure and consolidation approach. DFS, disease-free survival; GO, gemtuzumab ozogamicin; HSCT, hematopoietic stem cell transplant; KMT2A-r, KMT2A-rearranged; No-GO, did not receive GO; RR, relapse risk.